Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Active, not recruiting · NCT07162181 · Registry updated 2026-04-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-04-17 | NCT07162181 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eli Lilly and Company | 370 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Cancer hospital | Beijing | China | 84 |
| Blood Institute of the Chinese Academy of Medical science | Tianjin | China | 4 |
| Harbin Medical University Cancer Hospital | Harbin | China | 45 |
| Shanghai East Hospital | Shanghai | China | 12 |
| Sun Yat-Sen University Cancer Center | Guangzhou | China | 20 |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan | China | 26 |